Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      SOC Telemed Reports Second Quarter 2021 Financial and Operating Results

      Total system-wide consults of 130,200 during the second quarter an increase of 98% year over year

      Total system-wide core consults of 69,500 during the second quarter an increase of 130% year over year

      Bookings of $6.7 million in the second quarter an increase of 136% year over year

      Revenue of $25.0 million in the second quarter an increase of 84% year over year

      Revising FY21 revenue guidance lower to reflect temporary headwinds stemming from the COVID-19 delta variant

      (PRNewsfoto/Specialists On Call, Inc.)

      News provided by

      SOC Telemed

      Aug 12, 2021, 16:05 ET

      Share this article

      Share this article


      RESTON, Va., Aug. 12, 2021 /PRNewswire/ -- SOC Telemed, Inc., (NASDAQ: TLMD), the largest national provider of acute care telemedicine, today announced its financial and operating results for the second quarter ending June 30, 2021.

      "Our second quarter results reflect strong growth driven by a return to pre-COVID consult volumes in our telePsychiatry service line and a near return in our teleNeurology service line," said John Kalix, Chief Executive Officer of SOC Telemed. "Our late stage pipeline grew 30% since the first quarter. Such growth illustrates the expansive cross sell opportunity facing SOC Telemed, as we drive both site expansion and service line expansion across the client base."

      He further stated, "The ability to provide a comprehensive offering of clinical services combined with the Telemed IQ platform positions SOC Telemed to help solve our client's friction points around access to specialty physicians, network integrity, and optimization of clinician resources. As the largest acute telemedicine provider, we are well positioned to be the provider of choice as hospitals consolidate to a single vendor."

      Second Quarter and Recent Highlights

      • Announced a multi-site telePsychiatry service line expansion with UnityPoint Health for the Des Moines, Iowa, and Cedar Rapids, Iowa, markets, expected to go live in 2H21. UnityPoint Health's multi-site expansion was driven by the success case developed at UnityPoint Health Allen Hospital, which reduced average length of stay (ALOS) by approximately 12 hours, reduced its readmission rate by 4%, and avoided more than $1.7 million in annualized boarding costs, leading to an annual ROI of 281%
      • In May, we announced an expanded partnership with SCP Health (SCP). Under the multi-year agreement, SOC Telemed will provide the Telemed IQ platform to help accelerate and expand SCP's telehealth capabilities across the country
      • In April, Bon Secours Mercy – Lourdes Hospital implemented the teleICU service line, and Davis Regional Medical Center implemented the teleNeurology and teleStroke service lines

      Operating Metrics Summary

      Operational performance metrics for the three months ended June 30, 2021, compared to the three months ended June 30, 2020.  We present consults on a pro forma basis (i.e., giving retroactive effect to the Access Physicians acquisition to January 1, 2020) to provide investors with insight into how management views the performance of the combined business period over period.

      • Total system-wide consults were 130,214 compared to 65,690, up 98% year over year, and up 49% year over year on a pro forma basis
      • Stand-alone SOC core consults totaled 37,817 compared to 30,213, up 25% on a year over year basis. TelePsychiatry volumes recovered to pre-COVID levels faster than expected, and the teleNeurology service line experienced significant volume increases
      • Access Physicians contributed 31,700 core consults, up 47% on a year over year basis
      • System-wide revenue per core consult totaled $339 compared to $349, down 3%, primarily driven by the addition of Access Physicians, as revenue per core consult at Access Physicians is historically lower than revenue per core consult at legacy SOC. The average revenue per core consult is also impacted by duration of each consult, which varies widely between service lines
      • Stand-alone SOC revenue per core consult was $417 versus $429, as the volume recovery in telePsychiatry and teleNeurology narrowed the gap associated with minimum consult thresholds in client contracts
      • Access Physicians revenue per core consult was $245 versus $237, up 3% year over year, driven by service line volume mix
      • Implementations totaled 74 compared to 80, with Access Physicians contributing 11 implementations
      • Stand-alone SOC services per facility totaled 2.1 compared to 1.9, demonstrating the continued opportunity to expand across both service lines and sites with existing customers
      • Total facilities serviced were 1,028 compared to 847 a year ago, up 21% on a year over year basis. The 1,028 facilities serviced includes 179 facilities serviced by Access Physicians

      Financial Results Summary

      Financial performance for the three months ended June 30, 2021, compared to the three months ended June 30, 2020.

      • Bookings totaled $6.7 million, up 136%
      • Revenue totaled $25.0 million compared to $13.6 million, up 84%
      • Access Physicians contributed $8.4 million of revenue
      • GAAP gross profit totaled $8.0 million compared to $4.5 million
      • Adjusted gross profit (non-GAAP) totaled $9.3 million compared to $5.5 million
      • GAAP gross margin was 32% compared to 33%
      • Adjusted gross margin (non-GAAP) was 37% compared to 40%. Results were negatively impacted primarily by an increase in physician incentive payments related to the rapid increase and volatility of consult demand
      • Net loss totaled $(14.5) million compared to a net loss of $(8.2) million
      • Adjusted EBITDA loss totaled $(5.4) million compared to $(1.6) million

      Balance Sheet

      As of June 30, 2021, the Company had cash and cash equivalents of $50.0 million.

      In June 2021, SOC Telemed completed an underwritten follow-on public offering of 9.2 million shares generating net proceeds of approximately $52.0 million, after deducting underwriting discounts and offering expenses. 

      2021 Financial Outlook

      For the full year 2021, SOC Telemed is providing the following revised financial guidance:

      • GAAP Revenue is expected to be in the range of $90 million to $92 million, with approximately 30% expected to be attributed to Access Physicians
      • Primary drivers of the guidance revision include impacts from the Delta variant of COVID-19, specifically on increased pressure on hospital emergency departments, and a change in go-to-market strategy around hardware sales related to the integration of Access Physicians
      • The previous GAAP revenue guidance range was $97 million to $103 million, with approximately 30% to 35% expected to be attributed to Access Physicians
      • Adjusted gross margin is expected to be in the range of 37.0% and 40.0%
      • Adjusted EBITDA is expected to be in the range of $(22.0) million to $(25.0) million

      These statements are forward-looking and actual results may differ materially. Please refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

      SOC Telemed has not reconciled its expectations as to Adjusted Gross Margin and Adjusted EBITDA to the most comparable GAAP measures because certain items are out of its control or cannot be reasonably calculated or predicted at this time without unreasonable efforts. Accordingly, a reconciliation for forward-looking Adjusted Gross Margin and Adjusted EBITDA is not available without unreasonable effort.

      Upcoming Conferences and Investor Events

      Wells Fargo Virtual Healthcare Conference, September 9 – 10, 2021

      Baird 2021 Global Healthcare Conference, September 14 - 15, 2021

      Conference Call Details

      The second quarter 2021 earnings conference call and webcast will be held on August 12, 2021, at 5:00 p.m. ET. The conference call can be accessed by dialing, either:

      Domestic: (877) 870-4263

      International: (412) 317-0790

      Passcode: reference "SOC Telemed call"

      A live audio webcast will be available on the Investor Relations section of the Company website at investors.soctelemed.com. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link.

      About SOC Telemed

      SOC Telemed (NASDAQ: TLMD, "SOC") is the leading national provider of acute telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, and value-based care organizations since 2004. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC's technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a supportive and dedicated partner presence, virtually delivering patient care through teleNeurology, telePsychiatry, teleCritical Care, telePulmonology, teleCardiology, teleInfectious Disease, teleNephrology, teleMaternal-Fetal Medicine and other service lines, enabling healthcare organizations to build sustainable telemedicine programs across clinical specialties. SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes, and organizational health. The company was the first provider of acute clinical telemedicine services to earn The Joint Commission's Gold Seal of Approval and has maintained that accreditation every year since inception. For more information, visit www.soctelemed.com.

      Forward-Looking Statements

      This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify these forward-looking statements by the use of terms such as "expect," "will," "continue," or similar expressions, and variations or negatives of these words, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to: the statements under "2021 Outlook," including expectations relating to bookings and revenue; statements regarding relationships with customers and business momentum; statements regarding the expected benefits of the acquisition of Access Physicians (including anticipated synergies, projected financial information and future opportunities); and any other statements of expectation or belief. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied in this press release.  Such risk factors include, but are not limited to, those related to: the current and future impact of the COVID-19 pandemic on SOC Telemed's business and industry; continued difficulties in the integration of Access Physicians; the effects of competition on the future business of SOC Telemed; uncertainty regarding the demand for and market utilization of its solution; returns on investments in its business; the ability to maintain customer relationships; difficulties maintaining and expanding its network of qualified physicians and other provider specialists; disruptions in SOC Telemed's relationships with affiliated professional entities or third party suppliers or service providers; general business and economic conditions; the ability of SOC Telemed to successfully execute strategic plans; the timing and market acceptance of new solutions or success of new enhancements, features modifications to existing solutions and the degree to which they gain acceptance. Additional information concerning these and other risk factors is contained in the Risk Factors section of SOC Telemed's most recent annual report on Form 10-K. Additional information will be made available in SOC Telemed's quarterly report on Form 10-Q for the three months ended June 30, 2021, and other filings and reports that SOC Telemed may file from time to time with the SEC. SOC Telemed assumes no obligation, and does not intend, to update these forward-looking statements as a result of future events or developments.

      Use of Non-GAAP Financial Information

      We believe that, in addition to our financial results determined in accordance with GAAP, adjusted gross profit (non-GAAP), adjusted gross margin (non-GAAP), and adjusted EBITDA, all of which are non-GAAP financial measures, are useful in evaluating our business, results of operations, and financial condition.  However, our use of the terms adjusted gross profit, adjusted gross margin and adjusted EBITDA may vary from that of others in our industry. Adjusted gross profit, adjusted gross margin and adjusted EBITDA should not be considered as an alternative to gross profit, net loss, net loss per share or any other performance measures derived in accordance with GAAP as measures of performance. Adjusted gross profit, adjusted gross margin and adjusted EBITDA have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

      • adjusted EBITDA does not reflect the significant interest expense on our debt;
      • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin and adjusted EBITDA do not reflect any expenditures for such replacements; and
      • other companies in our industry may calculate these financial measures differently than we do, limiting their usefulness as comparative measures.

      We compensate for these limitations by using these non-GAAP financial measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include gross profit, net loss, net loss per share and other performance measures. In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. When evaluating our performance, you should consider these non-GAAP financial measures alongside other financial performance measures, including the most directly comparable GAAP measures set forth in the reconciliation tables below and our other GAAP results.

      Our non-GAAP financial measures are described as follows:

      Adjusted gross profit and adjusted gross margin. Adjusted gross profit is defined as revenues less cost of revenues plus depreciation and amortization plus equipment leasing costs plus stock-based compensation. Adjusted gross margin is adjusted gross profit divided by revenues.

      Adjusted EBITDA. Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, stock-based compensation, gain on contingent shares issuance liabilities, loss on puttable option liabilities, gain on change in fair value of contingent consideration, and integration, acquisition, transaction and executive severance costs.

      Readers are encouraged to review the reconciliation of our non-GAAP financial measures to the comparable GAAP results, which is attached to this earnings release and which can be found on SOC Telemed's investor relations page of its website at: investors.soctelemed.com.  

      Operating Metrics

      Because our consultation fee revenue generally increases as the number of visits increase, we believe the number of consultations provides investors with useful information on period-to-period performance as evaluated by management and as a comparison to our past financial performance. We define core consultations as consultations utilizing our 11 core services. Telemed IQ / other consultations are defined as consultations performed by other physician networks utilizing our technology platform, Telemed IQ. Pro forma consultations represent the number of total consultations as if Access Physicians had been acquired as of January 1, 2020.

      Number of Consults




      Q1 2020


      Q2 2020


      Q3 2020


      Q4 2020


      Q1 2021


      Q2 2021



      Core



      36,347




      30,213




      32,126




      30,920




      31,447




      37,817




      Access Physicians



      -




      -




      -




      -




      1,282




      31,700




      Telemed IQ / Other



      30,649




      35,477




      47,800




      57,292




      62,636




      60,697




      Total Consults



      66,996




      65,690




      79,926




      88,212




      95,365




      130,214





      Number of Pro Forma Consults




      Q1 2020


      Q2 2020


      Q3 2020


      Q4 2020


      Q1 2021


      Q2 2021



      Core



      36,347




      30,213




      32,126




      30,920




      31,447




      37,817




      Access Physicians



      20,067




      21,577




      26,357




      30,925




      33,399




      31,700




      Telemed IQ



      31,175




      35,777




      48,085




      57,642




      63,001




      60,697




      Total Consults



      87,589




      87,567




      106,568




      119,487




      127,847




      130,214






























      SOC Telemed, Inc. and Subsidiaries and Affiliates

      CONSOLIDATED BALANCE SHEETS

      (In thousands, except shares and per share amounts)

      (Unaudited)


      ASSETS


      June 30,
      2021



      December 31,
      2020

      CURRENT ASSETS




      Cash and cash equivalents (from variable interest entities $9,117 and $1,942,
      respectively)

      $      50,005


      $      38,754

      Accounts receivable, net of allowance for doubtful accounts of $468 and $447
      (from variable interest entities, net of allowance $13,067 and $8,192,
      respectively)

      14,438


      8,721

      Inventory

      1,356


      -

      Prepaid expenses and other current assets (from variable interest entities
      $130 and $0, respectively)

      4,997


      1,609

                    Total current assets

      70,796


      49,084





      Property and equipment, net

      3,970


      4,092

      Capitalized software costs, net

      10,062


      8,935

      Intangible assets, net

      46,204


      5,988

      Goodwill

      155,647


      16,281

      Deposits and other assets

      1,843


      559

      Total assets

      $     288,522


      $     84,939






      LIABILITIES AND STOCKHOLDERS' EQUITY




      Current liabilities




      Accounts payable (from variable interest entities $2,526 and $692,
      respectively)

      $      8,271


      $       2,809

      Accrued expenses (from variable interest entities $3,361 and $1,349,
      respectively)

      11,221


      8,293

      Deferred revenues

      531


      610

      Capital lease obligations

      22


      -

      Contingent consideration

      318


      -

      Stock-based compensation liabilities

      -


      4,228

                     Total current liabilities

      20,363


      15,940





      Deferred revenues

      1,012


      923

      Capital lease obligations

      52


      -

      Long term debt, net of unamortized discount and debt issuance costs

      73,563


      -

      Contingent shares issuance liabilities

      6,806


      12,450

      Other long-term liabilities (from variable interest entities $157 and $157,
      respectively)

      560


      560

      Total liabilities

      $   102,356


      $     29,873





      COMMITMENTS AND CONTINGENCIES








      STOCKHOLDERS' EQUITY




      Class A common stock, $0.0001 par value; 500,000,000 shares authorized as
         of June 30, 2021 and December 31, 2020; 98,233,640 and 74,898,380
         shares issued and outstanding at June 30, 2021 and December 31, 2020,
         respectively.

      10


      8

      Preferred stock, $0.0001 par value, 5,000,000 shares authorized; none issued
         and outstanding as of June 30, 2021 and December 31, 2020, respectively.

      -


      -

      Additional paid-in capital

      449,428


      291,277

      Accumulated deficit

      (263,272)


      (236,219)

         Total stockholders' equity (deficit)

      186,166


      55,066





      Total liabilities, contingently redeemable preferred
      stock and stockholders' equity




      $      288,522

      $      84,939


      SOC Telemed, Inc. and Subsidiaries and Affiliates

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (In thousands, except shares and per share amounts)

      (Unaudited)




      Three Months Ended
      June 30,



      Six Months Ended
      June 30,




      2021



      2020



      2021



      2020


      Revenues


      $

      24,960



      $

      13,554



      $

      39,781



      $

      28,361



















      Cost of revenues



      16,937




      9,030




      26,704




      19,743



















      Operating expenses

















      Selling, general and administrative



      22,479




      9,753




      43,740




      18,274


      Changes in fair value of contingent consideration



      (2,947)




      -




      (2,947)




      -


           Total operating expenses



      19,532




      9,753




      40,793




      18,274


           Loss from operations



      (11,509)




      (5,229)




      (27,716)




      (9,656)



















      Other income (expense)

















      Gain on contingent shares issuance liabilities



      2,192




      -




      5,644




      -


      Loss on puttable option liabilities



      -




      (96)




      -




      (105)


      Interest expense



      (3,123)




      (2,836)




      (3,272)




      (5,616)


      Interest expense – Related party



      (2,001)




      -




      (2,026)




      -


           Total other income (expense)



      (2,932)




      (2,932)




      346




      (5,721)


           Loss before income taxes



      (14,441)




      (8,161)




      (27,370)




      (15,377)



















      Income tax benefit (expense)



      (17)




      (2)




      317




      (3)



















      Net loss and comprehensive loss


      $

      (14,458)



      $

      (8,163)



      $

      (27,053)



      $

      (15,380)


      Accretion of contingently redeemable preferred stock



      -




      (2,023)




      -




      (3,518)


      Net loss attributable to common stockholders


      $

      (14,458)



      $

      (10,186)



      $

      (27,053)



      $

      (18,898)



















      Net loss per share attributable to common stockholders

















         Basic


      $

      (0.16)



      $

      (0.30)



      $

      (0.32)



      $

      (0.55)


         Diluted


      $

      (0.16)



      $

      (0.30)



      $

      (0.32)



      $

      (0.55)



















      Weighted-average shares used to compute net loss per
         share attributable to common stockholders:

















         Basic



      89,697,396




      34,345,197




      83,744,959




      34,345,197


         Diluted



      89,697,396




      34,345,197




      83,744,959




      34,345,197



      SOC Telemed, Inc. and Subsidiaries and Affiliates

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (In thousands)

      (Unaudited)




      Six Months Ended
      June 30,




      2021



      2020


      Cash flows from operating activities:







        Net loss


      $

      (27,053)



      $

      (15,380)


        Adjustments to reconcile net loss to net cash used in operating activities









      Depreciation and amortization



      4,141




      2,607


      Stock-based compensation



      10,644




      247


      Change in fair value of contingent consideration



      (2,947)




      -


      Loss on puttable option liabilities



      -




      105


      (Gain) on contingent shares issuance liabilities



      (5,644)





      -

      Bad debt expense



      47




      43


      Paid-in kind interest on long-term debt



      203




      1,527


      Amortization of debt issuance costs and issuance discount



      3,403




      710


      Income tax benefit



      (343)




      -


      Change in assets and liabilities, net of acquisitions









          Accounts receivable, net of allowance



      (162)




      2,981


          Prepaid expense and other current assets



      (2,752)




      (1,472)


          Inventory



      26




      -


          Deposits and other non-current assets



      (999)




      11


          Accounts payable



      2,647




      (921)


          Accrued expenses and other current liabilities



      742




      2,334


          Deferred revenues



      9




      143


       Net cash used in operating activities



      (18,038)




      (7,065)











      Cash flows from investing activities:









          Capitalization of software development costs



      (2,132)




      (2,090)


          Purchase of property and equipment



      (635)




      (1,222)


          Acquisition of business, net of cash



      (89,752)




      -


       Net cash used in investing activities



      (92,519)




      (3,312)











      Cash flows from financing activities:









          Principal payments under capital lease obligations



      -




      (45)


          Proceeds from long-term debt, net of discount



      83,219




      -


          Proceeds from Related-party – Unsecured subordinated promissory note



      11,500




      -


          Repayment of long-term debt



      (10,795)




      -


          Repayment of Related-party – Unsecured subordinated promissory note, net of
            unamortized discount



      (13,703)




      -


          Proceeds from exercise of stock options



      42




      -


          Issuance of contingently redeemable preferred stock



      -




      10,938


          Proceeds from issuance of Class A Common Stock, net of issuance costs



      51,545




      -


       Net cash provided by financing activities



      121,808




      10,893











      NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS



      11,251




      516


      Cash and cash equivalents at beginning of the period



      38,754




      4,541


      Cash and cash equivalents at end of the period


      $

      50,005



      $

      5,057











      SOC Telemed, Inc. and Subsidiaries and Affiliates

      RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

      (In thousands, except per share data) (Unaudited)




      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      Three Months Ended
      June 30,


      Six Months Ended
      June 30,



      2021


      2020


      2021


      2020


      2021


      2020


      2021


      2020











      Change


      % Change


      Change


      % Change



      (dollars in thousands)

      Revenues


      $

      24,960



      $

      13,554



      $

      39,781



      $

      28,361



      $

      11,406



      84

      %


      $

      11,420



      40

      %

      Cost of revenues



      16,937




      9,030




      26,704




      19,743




      7,907



      88

      %



      6,961



      35

      %

      Gross profit



      8,023




      4,524




      13,077




      8,618




      3,499



      77

      %



      4,459



      52

      %

      Add:































      Depreciation and amortization
      (a)



      1,222




      911




      2,444




      1,803




      311



      34

      %



      641



      36

      %

      Equipment leasing costs (b)



      4




      18




      8




      42




      (14)



      (78)

      %



      (34)



      (81)

      %

      Stock based compensation
      (e)



      6




      -




      6




      -




      6



      *




      6



      *


      Adjusted gross profit


      $

      9,255



      $

      5,453



      $

      15,535



      $

      10,463




      3,802



      70

      %



      5,072



      48

      %

      Adjusted gross margin
      (as a percentage revenues)



      37

      %



      40

      %



      39

      %



      37%



























      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      Three Months Ended
      June 30,


      Six Months Ended
      June 30,



      2021


      2020


      2021


      2020


      2021


      2020


      2021


      2020











      Change $


       Change %


      Change $


       Change %



      (dollars in thousands)

      Net loss


      $

      (14,458)



      $

      (8,163)



      $

      (27,053)



      $

      (15,380)



      $

      (6,295)



      77

      %


      $

      (11,673)



      76

      %

      Add:































      Interest expense (c)



      5,124




      2,836




      5,298




      5,616




      2,288



      81

      %



      (318)



      (6)

      %

      Income tax expense
      (benefit) (d)



      17




      2




      (317)




      3




      15



      *




      (320)



      *


      Depreciation and
      amortization (a)



      2,480




      1,317




      4,141




      2,607




      1,163



      88

      %



      1,534



      59

      %

      Stock-based
      compensation (e)



      4,786




      148




      10,644




      247




      4,638



      3,128

      %



      10,397



      4,209

      %

      Gain on contingent shares
      issuance liabilities (f)



      (2,192)




      -




      (5,644)




      -




      (2,192)



      *




      (5,644)



      *


      Loss on puttable option
      liabilities (g)



      -




      96




      -




      105




      (96)



      (100)

      %



      (105)



      (100)

      %

      Gain on change in fair
      value of contingent
      consideration (h)



      (2,947)




      -




      (2,947)




      -




      (2,947)



      *




      (2,947)



      *


      Integration, acquisition,
      transaction, and executive
      severance costs (i)



      1,772




      2,130




      5,909




      2,503




      (358)



      (17)

      %



      3,406



      136

      %

      Adjusted EBITDA


      $

      (5,418)



      $

      (1,634)



      $

      (9,969)



      $

      (4,299)




      (3,784)



      232

      %



      (5,670)



      132

      %


      * Percentage not meaningful




      For the Three Months Ended







      June 30, 2021


      June 30, 2020


      Change $


       Change %



      (dollars in thousands)



      Selling, general and administrative expenses (1)


      $

      22,479


      $

      9,753


      $

      12,726



      130

      %















      Sales and marketing



      2,397



      1,446



      951



      66

      %

      Research and development



      530



      255



      275



      108

      %

      Operations



      2,548



      2,088



      460



      22

      %

      General and administrative



      17,004



      5,964



      11,040



      185

      %



      $

      22,479


      $

      9,753


      $

      12,726



      130

      %

      (1)

      Selling, general, and administrative expenses include the following expenses for the periods presented:


      Three Months Ended June 30, 2021

      Three Months Ended June 30, 2020


      Stock-Based
      Compensation

      Depreciation and
      Amortization

      Integration
      Costs

      Stock-Based
      Compensation

      Depreciation
      and
      Amortization

      Integration
      Costs


      (dollars in thousands)

      Sales and marketing

      $

      73


      $

      —


      $

      —


      $

      8


      $

      —

      $

      —

      Research and development


      180



      —



      —



      33



      —


      —

      Operations


      184



      —



      —



      21



      —


      —

      General and administrative


      4,343



      1,303



      1,772



      86



      417


      2,130


      $

      4,780


      $

      1,303


      $

      1,772


      $

      148


      $

      417

      $

      2,130





















      For the Three Months Ended







      June 30, 2021


      June 30, 2020


      Change $


       Change %



      (dollars in thousands)



      Selling, general and administrative expenses excluding
      stock-based compensation, depreciation and
      amortization and integration costs


      $

      14,624


      $

      7,058


      $

      7,566



      107

      %















      Sales and marketing



      2,324



      1,438



      886



      62

      %

      Research and development



      350



      222



      128



      58

      %

      Operations



      2,364



      2,067



      297



      14

      %

      General and administrative



      9,586



      3,331



      6,255



      188

      %



      $

      14,624


      $

      7,058


      $

      7,566



      107

      %




      For the Six Months Ended







      June 30, 2021


      June 30, 2020


      Change $


       Change %



      (dollars in thousands)



      Selling, general and administrative expenses (1)


      $

      43,740


      $

      18,274


      $

      25,466



      139

      %















      Sales and marketing



      4,987



      2,985



      2,002



      67

      %

      Research and development



      1,058



      541



      517



      96

      %

      Operations



      5,062



      4,182



      880



      21

      %

      General and administrative



      32,633



      10,566



      22,067



      209

      %



      $

      43,740


      $

      18,274


      $

      25,466



      139

      %

      (1)

      Selling, general, and administrative expenses include the following expenses for the periods presented:


      Six Months Ended June 30, 2021

      Six Months Ended June 30, 2020


      Stock-Based
      Compensation

      Depreciation
      and
      Amortization

      Integration
      Costs

      Stock-Based
      Compensation

      Depreciation
      and
      Amortization

      Integration
      Costs


      (dollars in thousands)

      Sales and marketing

      $

      343


      $

      —


      $

      —


      $

      14


      $

      —

      $

      —


      Research and development


      274



      —



      —



      41



      —


      —


      Operations


      315



      —



      —



      34



      —


      —


      General and administrative


      9,705



      1,697



      5,909



      158



      815


      2,503



      $

      10,637


      $

      1,697


      $

      5,909


      $

      247


      $

      815

      $

      2,503
























      For the Six Months Ended







      June 30, 2021


      June 30, 2020


      Change $


       Change %



      (dollars in thousands)



      Selling, general and administrative expenses excluding
      stock-based compensation, depreciation and
      amortization and integration costs


      $

      25,497


      $

      14,709


      $

      10,788



      73

      %















      Sales and marketing



      4,644



      2,971



      1,673



      56

      %

      Research and development



      784



      500



      284



      57

      %

      Operations



      4,747



      4,148



      600



      14

      %

      General and administrative



      15,322



      7,090



      8,232



      116

      %



      $

      25,497


      $

      14,709


      $

      10,788



      73

      %

      Explanation of Non-GAAP Adjustments

      (a)   Depreciation and amortization consists primarily of depreciation of fixed assets, amortization of capitalized software development costs and amortization of acquisition-related intangible assets, such as customer relationships, non-compete agreements, and trade names acquired in connection with business combinations. While depreciation and amortization are non-cash charges, the assets being depreciated or amortized will often have to be replaced or updated in the future, and these measures do not reflect any cash requirements for these replacements or updates. Additionally, we incur amortization of acquisition-related intangible assets based on the portion of the purchase price allocated to intangible assets and the estimated useful lives of such assets. However, the purchase price allocated to these assets is not necessarily reflective of the cost we would incur to internally develop the intangible asset and we do not believe these charges are reflective of our operating results in the period incurred. We eliminate these non-cash charges from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.

      (b)   Equipment leasing costs consist of the cost of procuring telemedicine equipment through lease financing. We ceased this practice in the second quarter of 2017. We eliminate these charges from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.

      (c)   Interest expense consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with our term loan agreement. We eliminate these cash and non-cash expenses from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period within our presentation of adjusted EBITDA. Adjusted EBITDA is widely used by investors to measure a company's operating performance without regard to items, such as interest benefit and expense, income tax benefit and expense, depreciation and amortization, stock-based compensation, and other charges and income. We believe adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

      (d)   We incur income tax expenses or benefits that are related to prior periods. We eliminate these expenses from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period within our presentation of adjusted EBITDA.

      (e)   Stock-based compensation expense consists of expenses for stock options and other stock-based awards. Although stock-based compensation is a key incentive offered to our employees, we continue to evaluate our operating and financial performance excluding stock-based compensation expenses. Stock-based compensation expenses will recur in future periods. We evaluate our performance both with and without these measures because stock-based compensation is a non-cash expense and can vary significantly over time based on the timing, size, nature and design of the awards granted, and is influenced in part by certain factors that are generally beyond our control, such as the volatility of the market value of our common stock. In addition, we eliminate stock-based compensation expense from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.

      (f)  Gain on contingent share issuance liabilities consists of the change in fair value of 1,875,000 shares of our common stock held by HCMC's sponsor and subsequently distributed to permitted transferees and were modified and became subject to forfeiture in connects with the closing of our Merger Transaction, and 350,000 private placement warrants granted to HCMC's sponsor subsequently distributed to its permitted transferees as part of the Merger Transaction.  The contingent shares issuance liabilities are revalued at their fair value every reporting period.

      (g)   Loss on puttable option liabilities consists of changes in the fair value of puttable option liabilities. We eliminate these non-cash expenses from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.

      (h)   Gain on change in fair value of contingent consideration is the change in fair value of the earnout contingent consideration and the deferred payment in connection with our acquisition of Access Physicians in Q1 2021. The contingent consideration is revalued every reporting period based on the estimation of the likelihood that such contingent consideration will be earned. We eliminate these non-cash activities from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.

      (i)   Integration, acquisition, transaction and executive severance costs represent the transaction and business integration costs related to our business combination with Healthcare Merger Corp. in Q4 2020 and our acquisition of Access Physicians in Q1 2021.  These costs include incremental expenses incurred to affect business combinations such as advisory, legal, accounting, valuation, and other professional or consulting fees, as well as other related incremental executive severance costs. We exclude these costs from our non-GAAP results as they have no direct correlation to the operation of our business, and because we believe that the non-GAAP financial measures excluding these costs provide useful information about our spending trends to facilitate an understanding of our operating and financial performance from period-to-period.

      Media Relations: 

      Lauren Shankman 
      Trevelino/Keller 
      [email protected] 

      Investor Relations: 

      Steve Rubis 
      Vice President, Investor Relations 
      SOC Telemed 
      P: (214) 681-7991
      [email protected]  

      SOURCE SOC Telemed

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.